ClinicalTrials.gg
RecruitingNCT07753148Updated Nov 18, 2026

Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

A Phase 1 interventional study of REGN17235 in Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS), sponsored by Regeneron Pharmaceuticals. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 18, 2026Now RecruitingFirst sites in Belgium and United Kingdom+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies in Hematologic Neoplasms with a site in Belgium — 14 open to participants now, 20 under way, 5 of them phase 3. Hematologic Neoplasms · Belgium.

Planned enrollment
26th of 38
52 · median 111
Started
2026
with 3 others
Phase 1
6 of 43
3 open now
Primary completion
2031-05
later than 14 of 19 live
Registered
43rd of 43
by date

Among the 43 studies in Hematologic Neoplasms with a site in Belgium, this one is the 26th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 14 of the 19 other live ones, and was the 43rd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 423 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

14 of the 43 studies in Hematologic Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 210 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Hematologic Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

This study will test a study drug called REGN17235 (the "study drug") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic mutation (SF3B1 Mutation).

The study is looking at:

  • What side effects the study drug might cause
  • How well the study drug works
  • How much of the study drug is in the blood at different times
  • If the body makes antibodies (proteins that attach to substances your body does not recognize) against the study drug; this may cause the study drug to not work as well.
  • What is the best dose of the study drug to treat CCUS and LR-MDS
03

Conditions studied

  • Clonal Cytopenia of Undetermined Significance (CCUS)
  • Low-Risk Myelodysplastic Syndrome (LR-MDS)

Keywords

  • Blood cancer
  • First in human
  • Selective elimination of SF3B1-mutant cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Presence of SF3B1 mutation in the bone marrow or peripheral blood AND diagnosis of low-risk MDS OR diagnosis of CCUS as defined by WHO 2022, 5th edition as described in the protocol
  2. Adequate bone marrow function as described in the protocol; red blood cell transfusion dependence is permitted
  3. Adequate hepatic and renal function as described in the protocol

Key Exclusion Criteria:

  1. anemia due to non-MDS or non-CCUS etiologies (eg, iron deficiency, vitamin B12 or folate deficiency, or hereditary hemolysis, or hemorrhage) diagnosed or treated within the last 3 months prior to
  2. Recent or uncontrolled infections as described in the protocol
  3. Diagnosed or treated for other than MDS as described in the protocol
  4. Prior treatment with any systemic therapy for MDS or CCUS within 5 half-lives or within 14 days prior to first administration of study drug, whichever is shorter
  5. hematopoietic stem cell transplant within 100 days of enrollment or any signs or symptoms of ongoing (GVHD) as described in the protocol

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Part 1 Dose Escalation

    Drug: REGN17235

  • Experimental
    Part 2 Safety Expansion

    Drug: REGN17235

Interventions

  • DrugREGN17235

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 5 years

  2. Severity of TEAEs

    Time frame: Up to 5 years

  3. Occurrence of Serious Adverse Events (SAEs)

    Time frame: Up to 5 years

  4. Severity of SAEs

    Time frame: Up to 5 years

Secondary outcomes

  1. Hematologic improvement per International Working Group (IWG) 2018

    Time frame: Up to 5 years

  2. Concentration of REGN17235 in serum

    Time frame: Up to 5 years

  3. Occurrence of Anti-Drug Antibodies (ADA) to REGN17235 in serum

    Time frame: Up to 5 years

  4. Magnitude of ADA to REGN17235 in serum

    Time frame: Up to 5 years

07

Study locations

3 of 3 sites recruiting
  • Uz Ghent
    Ghent, 9000, Belgium
    Recruiting
  • Algemeen Ziekenhuis (AZ) Delta
    Roeselare, 8800, Belgium
    Recruiting
  • Kings College Hospital NHS Foundation Trust, King's College Hospital
    London, SE5 9RS, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2031, 55 months after the start.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 55 months is above that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 7, 2026
StartActual
Sep 17, 2026
Primary completionEst.
May 5, 2031
CompletionEst.
May 5, 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
3 sites added — first sites in Belgium and United Kingdom
Show 3 added (2 Belgium, 1 United Kingdom)
  • Uz Ghent · Ghent, Belgium
  • Algemeen Ziekenhuis (AZ) Delta · Roeselare, Belgium
  • Kings College Hospital NHS Foundation Trust, King's College Hospital · London, United Kingdom
across 2 updates, Oct 27, 2026 – Nov 18, 2026
Show all 2 updates
  1. Nov 18, 2026
    1 site added — first site in United Kingdom
    Show site
    • Kings College Hospital NHS Foundation Trust, King's College Hospital · London, United Kingdom
    + 1 other change: verification date
  2. Oct 27, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in Belgium
    Show 2 added (2 Belgium)
    • Uz Ghent · Ghent, Belgium
    • Algemeen Ziekenhuis (AZ) Delta · Roeselare, Belgium
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07753148
Responsible party
Sponsor
First posted
Aug 7, 2026
Start date
Sep 17, 2026
Primary completion
May 5, 2031 (estimated)
Completion
May 5, 2031 (estimated)
Last update
Nov 18, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion